Stocks · News reference

Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy

Jul 15, 2026, 6:11 PMVandana Singh

Ernexa Therapeutics reports independent preclinical validation of ERNA-101 with PD-1 therapy ahead of the planned 2026 IND filing.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 15, 2026, 6:11 PM
Checked: Jul 15, 2026, 6:11 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaJul 15, 2026, 2:09 PMBenzinga Newsdesk
Ernexa Therapeutics shares are trading higher after the company announced new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA-101, in combination with PD-1 checkpoint inhibition.
Read original at benzinga
ERNA
BenzingaJul 15, 2026, 1:43 PMAvi Kapoor
Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views
US stocks traded higher with Dow up 150 points. Consumer discretionary shares surged 1.3% while health care stocks fell 0.4%. Morgan Stanley beat earnings.
Read original at benzinga
AEHR CRDF ERNA LGHL MS
BenzingaJul 15, 2026, 11:53 AMBenzinga Newsdesk
Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced compelling new preclinical data independently
Read original at benzinga
ERNA